14 studies found for:    TRC105
Show Display Options
Rank Status Study
1 Completed
Has Results
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated
Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
2 Recruiting A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
Condition: Advanced Soft Tissue Sarcoma
Intervention: Drug: TRC105 and Pazopanib
3 Active, not recruiting Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: TRC105
4 Recruiting Sorafenib and TRC105 in Hepatocellular Cancer
Conditions: Hepatoma;   Liver Neoplasms;   Adenoma, Liver Cell;   Carcinoma, Hepatocellular;   Liver Neoplasms, Experimental
Interventions: Drug: TRC 105;   Drug: Sorafenib
5 Recruiting Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Recurrent Adult Brain Tumor
Interventions: Biological: anti-endoglin monoclonal antibody TRC105;   Biological: bevacizumab;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: quality-of-life assessment
6 Completed Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Conditions: Recurrent Ovarian Cancer;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
7 Recruiting A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Condition: Renal Cell Carcinoma
Intervention: Drug: TRC105 and Axitinib
8 Terminated
Has Results
TRC105 for Recurrent Glioblastoma
Condition: Glioblastoma Multiforme
Intervention: Drug: TRC105
9 Active, not recruiting TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma
Conditions: Urothelial Carcinoma;   Ureteral Neoplasms;   Ureter Cancer;   Neoplasm, Ureteral;   Cancer of the Ureter
Intervention: Drug: TRC105
10 Active, not recruiting Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Biological: bevacizumab;   Biological: anti-endoglin monoclonal antibody TRC105;   Other: laboratory biomarker analysis;   Other: pharmacological study
11 Completed Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer
Conditions: Cancer;   Neoplasm Metastasis
Intervention: Drug: TRC105 chimeric anti-CD105 antibody
12 Active, not recruiting TRC105 for Liver Cancer That Has Not Responded to Sorafenib
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Carcinoma, Hepatocellular
Intervention: Drug: TRC105
13 Completed A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)
Conditions: Prostate Cancer;   Metastatic Castrate Resistant Prostate Cancer
Intervention: Drug: TRC105
14 Active, not recruiting A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab for the Treatment Of Recurrent or Progressive Glioblastoma That Has Progressed on Bevacizumab
Conditions: Glioblastoma;   Glioblastoma Multiforme
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105

Indicates status has not been verified in more than two years